Australia’s Therapeutic Goods Administration (TGA) has added galactooligosaccharides (GOS) to its Permissible Ingredients Determination for listed complementary medicines in Australia, announced GOS ingredient supplier FrieslandCampina Ingredients.
FrieslandCampina Ingredients (Amersfoort, the Netherlands), a supplier of the Biotis brand of prebiotic galactooligosaccharides (GOS), announced that Australia’s Therapeutic Goods Administration (TGA) has added GOS to its Permissible Ingredients Determination for listed complementary medicines in Australia. As a result, FrieslandCampina says it now has exclusive rights, for two years, to supply Biotis GOS for new prebiotic supplements in Australia.
The company says that Australia’s market is ripe for prebiotic products. The company cites data it gathered in 2022 with Nielsen IQ showing that 40% of Australian consumers say gut health is extremely important to them, with 30% of Australian consumers saying they suffer from gut-related issues. Consumer recognition of prebiotics is also good in the area, with data showing that 53% of consumers in Australia are already aware of prebiotics and with 54% understanding prebiotics’ digestive health benefits.
The Biotis GOS line also includes FrieslandCampina’s recently introduced Biotis GOS-OP High Purity ingredient designed to make formulating prebiotic supplements easier due to its high concentration, enabling efficacious doses at as low as 2 g.
“The news that we have received approval from the TGA means that we can help brands across Australia meet these demands [for trending supplement delivery formats] with our specifically designed and easy-to-formulate prebiotic solutions,” said Job van Rozendaal, managing director, Asia Pacific, FrieslandCampina Ingredients, in a press release.